Navigation Links
Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Date:10/14/2008

ice of National Drug Control Policy

Jeff Gudin, M.D., Co-Director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey

Steve Passik, Ph.D., Associate Attending Psychologist at Memorial Sloan-Kettering Cancer Center in New York

Jennifer Bolen, J.D., a patient living with chronic pain and founder of The Legal Side of Pain, a Tennessee-based organization that provides legal guidance regarding use of pain medications

Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [CII], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... The North American crystal oscillator market report defines ... and forecast of revenue. This market was valued at ... $623.6 million by 2018, at a CAGR of 3.3% ... of the North American crystal oscillator market report, to ... also provides a glimpse of the segmentation of the ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... and year-end 2008 financial results on Wednesday, February 4, ... be followed by a conference call at 5:00 p.m. ... telephone and webcast. During the conference call, the company ...
... a,subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), is issuing, ... 26, 2009, a nationwide,voluntary recall of the products ... a wholesale or a retail level as a ... conditions that did not,sufficiently comply with current Good ...
... Japan,s first second-generation drug-eluting stentNATICK, Mass., Jan. 28 ... ) announced today that it has received approval ... Welfare (MHLW) to market its TAXUS(R) Liberte(R) Paclitaxel-Eluting ... launch the product as soon as reimbursement approval ...
Cached Biology Technology:Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 4ETHEX Corporation Issues Nationwide Voluntary Recall of Products 5ETHEX Corporation Issues Nationwide Voluntary Recall of Products 6Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 3
(Date:10/25/2014)... Research and Markets  has announced the addition of ... to their offering. Biometrics is a ... of their physical or behavioral patterns. It involves the ... fingerprints, face recognition, DNA, palm print, hand geometry, and ... and speech pattern/voice recognition. The data ...
(Date:10/22/2014)... -- Leading identity analyst firm Acuity Market Intelligence forecasts that ... will have a chip-based National eID card, including near-complete ... Asia , with its vast population, is ... 60% of all National eID cards issued between 2014 ... National eID Industry Report: 2014 Edition" — ...
(Date:10/18/2014)... 19th October 2014 Psychological stress and stress-related psychiatric ... aging-related diseases, but the molecular mechanisms underlying ... may contribute to the development of targeted ... for these devastating diseases. This work is ... congress in Berlin., Now an international group ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... the atmosphere and moving into marine systems, the world,s ... To address the growing concern for acidifying marine systems, ... under the Ocean Acidification theme of its Climate Research ... Office of Polar Programs, Directorate for Geosciences, and Directorate ...
... October 13, 2010) Before Alzheimer,s patients experience memory loss, ... A new study in mouse models by researchers ... mitochondria -- the powerhouses of the cell -- are one ... appeared in the online Early Edition of PNAS, also found ...
... North American comb jellyfish can sneak up on its ... successful predator. Researchers, including one from the University of ... jellyfish makes itself hydrodynamically ,invisible,. The North American ... known to consume vast quantities of zooplankton. A few ...
Cached Biology News:NSF awards grants to study effects of ocean acidification 2NSF awards grants to study effects of ocean acidification 3NSF awards grants to study effects of ocean acidification 4NSF awards grants to study effects of ocean acidification 5NSF awards grants to study effects of ocean acidification 6NSF awards grants to study effects of ocean acidification 7NSF awards grants to study effects of ocean acidification 8NSF awards grants to study effects of ocean acidification 9NSF awards grants to study effects of ocean acidification 10Early role of mitochondria in AD may help explain limitations to current beta amyloid hypothesis 2Voracious comb jellyfish 'invisible' to prey 2